Earnings ·
Reports Q3 net sales of $874.5M, raises full-year guidance to $3.41B-$3.42B
WSTWest Pharmaceutical Services Inc
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, an 8.7% increase from the prior year period, driven by strong performance in its High-Value Product Components business which grew 19.7%. Diluted earnings per share rose to $3.02, up 57.3%, while adjusted diluted EPS increased 35.7% to $2.66. The company raised its full-year 2026 net sales guidance to a range of $3.41 billion to $3.42 billion and adjusted diluted EPS guidance to $9.38-$9.48, citing robust execution and margin expansion. West repurchased $231 million of stock in the quarter and declared a fourth-quarter dividend of $0.26 per share. The company operates as a leading provider of innovative injectable solutions and services for pharmaceutical companies.